Assessment of the effect of transurethral intraprostatic injection of botolinum toxin type A on males with chronic pelvic pain syndrome & refractory to conventional therapy referred to Razi hospital

rology Research Center0 个研究点目标入组 60 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•age>18; clinical diagnosis of CPPS defined as symptoms of discomfort or pain in the perineal or pelvic region for at least the past 3 months without evidence of bacterial infection; aggregate score of greater than or equal to 10 on the NIH-CPSI questionair; failed empirical therapy for 4-6 weeks
•Exclusion criteria: history of prostate; bladder or urethra cancer; pelvic radiation or systemic chemotherapy or intravesical chemotherapy; neurological disease affectin g the bladder; previous intraprostatic injection of BoNT-A; PVR>200 cc; history of prostate surgery; urinary catheter; cystostomy or nephrostomy; penile or urinary sphincter implants; PSA > age- specific range; coagulopathies; during the last month: intake of antibiotics,alpha-receptor blockers,anticholinergics; intake of analgesics containing opioids; during the last 3 months:documented urinary infection,epididymitis,positive urinary cultures,STD; during the last 6 months:5-alpha reductase inhibitor; during the last 12 months: genital herpes, not adjustable HTN; angina pectoris; heart failure; status post MI; coronary bypass surgery or coronary dilatation; during the last 24 months: cerebral insult; serum creatinin >2 mg/dl; hypersensitivity concerning any substances of content of BoNT-A or myasthenia gravis; abuse of drugs or alcohol during last 5 years

发起方

rology Research Center